Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/19/2025

Diagnosis and Management of Hematologic Malignancies

Introduction to Diagnostic Techniques

  • The National Comprehensive Cancer Network recommends morphologic assessment of blood cells to identify characteristic cell features specific to different leukemia types, such as hairy cell projections in hairy cell leukemia, small mature lymphocytes with dense nuclei in chronic lymphocytic leukemia, and immature blast cells in acute leukemias 1
  • A Complete Blood Count (CBC) with differential and peripheral blood smear review is essential to evaluate for cytopenias affecting multiple cell lines, identify the presence of abnormal cells/blasts, and provide baseline hematologic parameters, as recommended by the National Comprehensive Cancer Network and the European Society for Medical Oncology 2, 3

Immunophenotyping

  • The European Society for Medical Oncology suggests immunophenotyping by flow cytometry to identify specific cell surface markers, such as CD5, CD19, CD20, CD23 positivity for chronic lymphocytic leukemia 4
  • The International Society for Laboratory Hematology recommends immunophenotyping by flow cytometry to identify specific cell surface markers, such as CD19, CD20, CD11c, CD25, CD103, CD123, CD200 positivity for hairy cell leukemia 5
  • Quantitative Immunoglobulins measure serum IgG, IgA, and IgM levels, and consider IgG subclasses if indicated by clinical presentation, particularly relevant in suspected antibody deficiencies or B-cell lymphomas, as stated by the American Academy of Allergy, Asthma, and Immunology and the National Comprehensive Cancer Network 6, 7, 8, 3

Molecular Testing

  • The American College of Medical Genetics and Genomics recommends FISH or RT-PCR for molecular diagnosis of BCR-ABL1 fusion in chronic myeloid leukemia, and other specific gene rearrangements 9
  • Fluorescence In Situ Hybridization (FISH) detects specific chromosomal abnormalities, such as BCR-ABL1 for CML, KMT2A translocations, and ETV6-RUNX1, as recommended by the National Comprehensive Cancer Network 9, 10
  • Interphase FISH assays are necessary for detecting major recurrent genetic abnormalities, including BCR-ABL1, ETV6-RUNX1, KMT2A translocations, hyperdiploidy markers, and CDKN2A deletions, as stated by the National Comprehensive Cancer Network and the Journal of Clinical Oncology 2, 7

Bone Marrow Examination

  • The National Comprehensive Cancer Network suggests bone marrow examination with cytogenetics and molecular testing for mutations, such as KIT, FLT3-ITD, NPM1, CEBPA, in patients with abnormal blood findings 1
  • Bone marrow aspiration and biopsy, morphologic examination, flow cytometry for immunophenotyping, and cytogenetic analysis are indicated when peripheral blood tests suggest hematologic malignancy, as recommended by the American College of Medical Genetics and Genomics 9
  • Karyotyping of G-banded metaphase chromosomes (conventional cytogenetics) is a crucial component of bone marrow examination, as recommended by the National Comprehensive Cancer Network 2

Prognostic Markers

  • Serum calcium and creatinine are recommended as prognostic markers for plasma cell disorders, including multiple myeloma, as recommended by the International Myeloma Society 11, 12
  • Beta-2 microglobulin is a prognostic marker for plasma cell disorders, including multiple myeloma, as recommended by the International Myeloma Society 11, 12
  • The FLIPI and IPI parameters are used for prognostic scoring, as defined by the International Lymphoma Study Group 13, 14, 15, 16, 3, 17
Parameter Description
Hemoglobin level <12 g/dL is adverse factor
LDH Elevated is adverse factor
Age
Stage
Number of nodal sites
Parameter Description
--- ---
LDH Elevated is adverse factor
Age
Stage
Performance status
Extranodal sites

Imaging Studies

  • A Chest X-ray is necessary to rule out mediastinal masses, as recommended by the National Comprehensive Cancer Network 2
  • A CT scan of chest/abdomen/pelvis with contrast is recommended if lymphoma or other malignancy is suspected based on clinical findings, as suggested by the National Comprehensive Cancer Network 8 and 18
  • CT/MRI scan of the head with contrast is recommended if neurologic symptoms are observed, as stated by the National Comprehensive Cancer Network 2
  • Whole body PET/CT scan is recommended if lymphoblastic lymphoma is suspected and essential for lymphoma staging, as recommended by the National Comprehensive Cancer Network 2
  • FDG-PET/CT scan is recommended for staging, according to the European Society for Medical Oncology and the National Comprehensive Cancer Network 3, 13, 16, 8

Laboratory Tests

  • Serum Protein Electrophoresis (SPEP) and Immunofixation Electrophoresis (IFE) are essential for detecting monoclonal proteins (M-proteins) and critical for diagnosing plasma cell disorders, including multiple myeloma, as recommended by the National Comprehensive Cancer Network 11, 12
  • Serum Free Light Chain Assay is recommended to detect excess kappa or lambda light chains, which is important for diagnosing and monitoring plasma cell disorders, as recommended by the American Society of Clinical Oncology 11, 12
  • Lactate dehydrogenase (LDH) testing is recommended, as elevated levels are associated with lymphoproliferative disorders and other malignancies, as recommended by the National Comprehensive Cancer Network 8
  • Elevated basophils (>0.43 × 10^9/L) are highly sensitive for Chronic Myeloid Leukemia (CML), as recommended by the National Comprehensive Cancer Network 10
  • Neutrophil alkaline phosphatase (NAP) score is a useful marker for diagnosing CML, as recommended by the American Society of Clinical Oncology 10

Management and Monitoring

  • Discontinue suspected causative medications when possible, as recommended by the Journal of Clinical Oncology and the American Society of Clinical Oncology 19, 7
  • Hematology consultation is recommended for persistent unexplained lymphocytopenia, as recommended by the American Society of Clinical Oncology 7
  • Regular CBC monitoring until resolution of leukopenia is necessary, with frequency depending on severity and underlying cause, as recommended by the American Society of Clinical Oncology 7
  • Treatment of underlying autoimmune conditions, such as rheumatologic disorders, may involve immunosuppressive therapy in severe cases, according to the European League Against Rheumatism (EULAR) guidelines and the American College of Rheumatology 20
  • Monitoring with repeat CBCs every 4-8 weeks is recommended for patients with lymphopenia, although the specific guideline society is not mentioned in the provided text
  • Urgent hematology consultation, immediate bone marrow evaluation, and consideration of prophylactic antibiotics if neutropenic may be necessary depending on clinical status, although the specific guideline society is not mentioned in the provided text
  • Bone marrow aspiration and biopsy should be considered in scenarios such as persistent unexplained lymphopenia, presence of other cytopenias, abnormal cells on peripheral blood smear, or suspected hematologic malignancy, although the specific guideline society is not mentioned in the provided text
  • Bone marrow evaluation should include morphologic examination, flow cytometry, cytogenetic analysis, and FISH for recurrent genetic abnormalities, although the specific guideline society is not mentioned in the provided text

Complement Function Tests

CH50 AH50 Interpretation
Normal Normal Normal complement function
Normal Low Properdin defect
Normal Zero Factor B or D defect
Low Normal/Low Regulatory component defect
Zero Normal C1, C2, or C4 deficiency
Zero Zero C3 or C5-C9 deficiency
  • CH50 and AH50 assays screen for classical and alternative pathway defects, with interpretation guide provided, as recommended by the American Academy of Allergy, Asthma, and Immunology 6

Antibody Response Testing

Age Response Criteria
<6 years Mild: >1.3 mg/mL for >50% of serotypes with 2-fold increase for <50%, Moderate: >1.3 mg/mL for <50% of serotypes
>6 years Mild: >1.3 mg/mL for >70% of serotypes with 2-fold increase for <70%, Moderate: >1.3 mg/mL for >70% of serotypes, Severe: >1.3 mg/mL for ≤2 serotypes
  • Antibody Response Testing assesses protein antigen response (tetanus, diphtheria) and polysaccharide antigen response (pneumococcal), and evaluates both pre- and post-vaccination titers, with response criteria varying by age, as recommended by the American Academy of Allergy, Asthma, and Immunology 6

REFERENCES

1

acute myeloid leukemia, version 3.2017, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

8

non-hodgkin's lymphomas. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2011

12

nccn clinical practice guidelines in oncology: multiple myeloma. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2009

18

hodgkin lymphoma, version 2.2020, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2020